Functional loss of B-cell maturation antigen (BCMA) is a recognised mechanism of relapse after BCMA-directed chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory multiple myeloma. Targeting multiple tumour antigens simultaneously with a single CAR has the potential to mitigate antigen escape and prolong disease responses.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with MGH
Contact MGH, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack